- Home
- ELDN vs EYPT Comparison
ELDN vs EYPT Comparison
Compare ELDN & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELDN | EYPT |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.8M | 273.3M |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ELDN | EYPT |
|---|---|---|
| Price | $2.13 | $2.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $9.00 | ★ $25.91 |
| AVG Volume (30 Days) | 758.2K | ★ 3.0M |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $967.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $2.93 |
| 52 Week High | $4.60 | $19.11 |
Technical Indicators
Market Signals| Indicator | ELDN | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 25.06 | 31.68 |
| Support Level | $1.96 | N/A |
| Resistance Level | $2.30 | $3.57 |
| Average True Range (ATR) | 0.13 | 0.20 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 6.00 | 12.53 |
Price Performance
Historical ComparisonAbout ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.